Monocarboxylate Transporter 8 (MCT8) deficiency
Rare Thyroid Therapeutics International AB focuses on Monocarboxylate Transporter 8 (MCT8) deficiency, a rare disorder affecting thyroid hormone transport and related neurological development. Its clinical research is centred on patients with this inherited condition, with particular attention to males and young children affected by impaired triiodothyronine (T3) regulation.
- Thyroid hormone transport disorders
- Triiodothyronine (T3) physiology
- Rare paediatric endocrine disease
The sponsor’s studies reflect a medical interest in the endocrine and neurological consequences of MCT8 deficiency, including the management of abnormal thyroid hormone profiles and the clinical features associated with this rare genetic condition.
Neurodevelopment in early childhood
Another key area of interest is neurodevelopmental impairment in infants and young children with MCT8 deficiency. The research landscape includes assessment of gross motor function, motor skills, and early developmental progress in very young boys, with emphasis on the impact of treatment on functional development during infancy and toddlerhood.
- Gross motor development
- Infant developmental assessment
- Paediatric motor function
This work places strong therapeutic focus on developmental outcomes in early life, where neurological disability is a central concern in the course of the disease.
Thyroid hormone treatment management
The sponsor also investigates thyroid hormone replacement and maintenance strategies in patients with MCT8 deficiency, with attention to the effects of continuing or stopping tiratricol on circulating triiodothyronine levels. This area of research is linked to the biochemical control of thyroid hormone activity in a rare transporter defect.
- Tiratricol therapy
- Serum T3 concentration monitoring
- Endocrine biomarker assessment
Clinical interest extends to how sustained treatment influences hormonal balance in affected males with stable maintenance therapy.
Rare disease paediatrics
Rare Thyroid Therapeutics International AB is active in paediatric rare disease research, particularly in children under 30 months of age with a severe inherited endocrine-neurological condition. Its studies are directed toward the specialised needs of young patients who require long-term clinical follow-up in a rare disorder setting.
- Infant and toddler care
- Inherited endocrine disorders
- Long-term paediatric follow-up
The sponsor’s therapeutic interest lies in addressing the clinical burden of early-onset MCT8 deficiency through ongoing paediatric investigation.
